drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T; biological, gene-modified T-cell immunotherapy)
drug_description
Autologous, gene-modified T cells engineered to express a chimeric antigen receptor that binds CD19; administered as a single IV infusion to activate cytotoxic T-cell killing of CD19+ B-lineage cells, leading to B-cell depletion and reduced autoantibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a chimeric antigen receptor that binds CD19 on B-lineage cells. Upon engagement, CAR-T cells activate and mediate cytotoxic killing (perforin/granzyme and cytokines), leading to profound depletion of CD19+ B cells/plasmablasts, reduction of autoantibody production, and functional resetting of humoral immunity.
drug_name
CD19-targeted CAR-T cells
nct_id_drug_ref
NCT06056921